 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: LEMTRADA (Campath, alemtuzumab) |
|
***************************************************** |
|
#Post#: 2517-------------------------------------------------- |
|
EMA to restrict use of alemtuzumab pending review |
|
By: agate Date: May 14, 2019, 8:34 pm |
|
--------------------------------------------------------- |
|
The concern about stroke risk has prompted the European |
|
Medicines Agency to restrict the use of alemtuzumab pending |
|
review. From The Lancet (April 27, 2019), "Alemtuzumab to be |
|
restricted pending review, says EMA": |
|
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30935-3/full… |
|
***************************************************** |
